title: alpha-Synuclein protects SH-SY5Y cells from dopamine toxicity.
abstract: Dopaminergic human neuroblastoma SH-SY5Y cells were stably transformed to increase expression of alpha-synuclein, a Parkinson's disease-related protein. Transformed cells were more resistant to oxidative insults, showing a cytoprotective role of alpha-synuclein. The expression of redox chaperonins (DJ-1, HSP70, and 14-3-3) was evaluated by Western blotting. Expression of alpha-synuclein reduced HSP70 levels even in the presence of dopamine, with a twofold increase of DJ-1 in the absence of oxidants. DJ-1 is significantly reduced by dopamine, and even more by dopamine and Cu(II). Increased alpha-synuclein expression did not affect 14-3-3, although dopamine increased its level by 60% in wild-type cells. alpha-Synuclein not only upregulated DJ-1, but also shifted all DJ-1 forms to a single spot at pI=5.7 not observed in wild-type cells. Dopamine gradually restored the distribution of DJ-1 forms to a situation similar to wild-type cells, with the form at pI=6.1 progressively enriched under oxidative conditions.
authors.affiliation: Department of Structural and Functional Biology, and Centre of Neuroscience, University of Insubria, Via Alberto da Giussano 12, 21052 Busto Arsizio, VA, Italy.
authors.forename: Monica
authors.initials: M
authors.lastname: Colapinto
authors.forename: Silvia
authors.initials: S
authors.lastname: Mila
authors.forename: Sabrina
authors.initials: S
authors.lastname: Giraudo
authors.forename: Paola
authors.initials: P
authors.lastname: Stefanazzi
authors.forename: Monica
authors.initials: M
authors.lastname: Molteni
authors.forename: Carlo
authors.initials: C
authors.lastname: Rossetti
authors.forename: Bruno
authors.initials: B
authors.lastname: Bergamasco
authors.forename: Leonardo
authors.initials: L
authors.lastname: Lopiano
authors.forename: Mauro
authors.initials: M
authors.lastname: Fasano
mesh_terms: D017209:Apoptosis / Q000187:drug effects*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects*; D004298:Dopamine / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D006801:Humans; D009447:Neuroblastoma / Q000473:pathology*; D051844:alpha-Synuclein / Q000008:administration & dosage*
chemical_list: D004338:Drug Combinations; D051844:alpha-Synuclein; D004298:Dopamine